While precision medicine has focused on tumor biology, this research suggests a broader "precision care" approach is needed. This involves tailoring treatment, such as drug dosage, based on patient-specific factors like physiology, functional reserve, and personal goals, not just genomic markers.

The trillions of microbes in our gut are not passive residents; they engage in a constant dialogue with immune cells. This "conversation" is critical for calibrating the immune system, teaching it what to attack (pathogens) and what to tolerate (food, benign germs), preventing both infections and autoimmunity.

The gut microbiome exists in a stable state with a resilience that makes it difficult to alter permanently. After short-term disruptions like antibiotics or diet changes, it often 'snaps back' to its original composition. This means meaningful, long-term change requires sustained effort to establish a new, stable microbial state rather than temporary interventions.

Butyrate, a short-chain fatty acid from gut bacteria, functions similarly to HDAC inhibitor drugs used in cancer therapy. This provides a scientific mechanism for how diet impacts myeloma, revealing its role in anti-tumor and anti-inflammatory pathways.

While you inherit a small fraction of your genetics from your parents, the vast majority of your genetic material comes from the 38 trillion microorganisms in your gut. This microbial DNA is dynamic and shaped by your environment and lifestyle choices, giving you significant influence over your genetic expression.

Despite billions invested over 20 years in targeted and genome-based therapies, the real-world benefit to cancer patients has been minimal, helping only a small fraction of the population. This highlights a profound gap and the urgent need for new paradigms like functional precision oncology.

Studies of traditional populations show their microbiomes are vastly different from those in industrialized nations. This suggests that what is considered a 'healthy' American microbiome might actually be a perturbed state, silently predisposing individuals to chronic inflammatory and metabolic diseases due to factors like antibiotics and diet.

Unlike using genetically identical mice, Gordian tests therapies in large, genetically varied animals. This variation mimics human patient diversity, helping identify drugs that are effective across different biological profiles and addressing patient heterogeneity, a primary cause of clinical trial failure.

Biomarkers provide value beyond predicting patient response. Their core function is to answer 'why' a treatment succeeded or failed. This explanatory power informs sequential therapy decisions and provides crucial scientific insights that advance the entire medical field, not just the individual patient's case.